Esketamine Adverse Events Meta-Analysis for Treatment-Resistant Depression

A systematic review and meta-analysis of nine randomized controlled trials involving 1,449 patients, conducted by Yang Qu and published in 2026. It evaluates the dose-dependent safety profile of esketamine for treatment-resistant depression. The analysis includes data from international and Mainland China studies up to March 2025.

Use Cases

• Analyze dose-response relationships for adverse events based on dosage ranges and administration routes mentioned in the description
• Compare safety profiles across geographic regions based on the subgroup analysis of Mainland China versus International multi-regional studies
• Assess the risk-benefit trade-off of esketamine therapy based on clinical response and treatment discontinuation rates

Strengths

• Includes data from nine randomized controlled trials with 1,449 patients
• Provides specific risk ratios for adverse events like nausea (RR 3.72 vs 1.69) and dissociation (RR 10.65 vs 3.27) by dose group
• Conducts subgroup analyses by dosage, administration route, and geographic region

Limitations

• The dataset is a summary document (DOCX) of 11.3 KB; the underlying raw data tables are not provided
• Column-level documentation is absent; field semantics must be inferred from the article text
• Row count for the original trial data is unknown, which may limit suitability assessment

Provenance

Source

Yang Qu via figshare

Collection Method

Systematic review and meta-analysis of randomized controlled trials sourced from PubMed, Embase, Cochrane Library, CBM, CNKI, and Wanfang databases.

Time Range

Trials from database inception to March 2025.

Freshness

Last updated 2026-05-28 06:23:30

Geography

International, with subgroup analysis for Mainland China versus International multi-regional studies.